Ashish V Chintakuntlawar
Overview
Explore the profile of Ashish V Chintakuntlawar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
813
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calcano G, Rourk K, Routman D, OByrne J, Chintakuntlawar A, Garcia J, et al.
Otolaryngol Head Neck Surg
. 2025 Jan;
PMID: 39764676
Objective: Margin distance is a significant prognosticator in oral cavity cancer but its role in HPV-related oropharyngeal squamous cell carcinoma [HPV(+)OPSCC] remains unclear. Here, we investigate the impact of margin...
2.
Lee K, Morris 3rd J, Kumar A, Chintakuntlawar A, Peskey C, Hilger C, et al.
Head Neck
. 2024 Oct;
47(3):813-821.
PMID: 39462887
Background: The overall survival of patients with advanced thyroid cancers that have progressed following targeted therapies is limited, indicating a strong need for salvage treatments. Methods: We retrospectively analyzed patients...
3.
Chandani K, Agrawal S, Raval M, Siddiq S, Nadeem A, Chintakuntlawar A, et al.
Medicina (Kaunas)
. 2024 May;
60(5).
PMID: 38792983
: Non-Hodgkin lymphoma (NHL) has the sixth-highest malignancy-related mortality in the United States (US). However, inequalities exist in access to advanced care in specific patient populations. We aim to study...
4.
Cooper A, Fazer C, Chintakuntlawar A, Fuentes Bayne H, McGarrah P, Price K
J Adv Pract Oncol
. 2024 Jan;
14(7):571-575.
PMID: 38196671
Background: Patients with metastatic human papillomavirus-associated oropharyngeal cancer (HPV-OPC) have a median overall survival exceeding 2 years and are often candidates for multiple lines of palliative therapy. With the approval...
5.
Laughlin B, Ebrahimi S, Voss M, Patel S, Foote R, McGee L, et al.
Adv Radiat Oncol
. 2023 May;
8(4):101204.
PMID: 37152485
Purpose: This series reports long-term clinical outcomes of patients with salivary duct carcinoma (SDC), which is associated with a poor prognosis. Methods And Materials: Eighty-nine patients with SDC were treated...
6.
Yin L, Routman D, Day C, Harmsen W, Haller T, Bartemes K, et al.
Head Neck
. 2022 Sep;
44(12):2760-2768.
PMID: 36129387
Background: We aim to explore the prognostic role of absolute lymphocyte count (ALC) before, during, and after treatment on oncologic outcomes in human papillomavirus associated oropharyngeal cancer (HPV(+)OPSCC). Methods: Retrospective...
7.
Karp E, Yin L, OByrne T, Lu L, Routman D, Lester S, et al.
Laryngoscope
. 2022 Jul;
133(6):1394-1401.
PMID: 35851669
Objective: Failure to recognize symptoms of non-human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV(-)OPSCC) at presentation can delay diagnosis and treatment. We aim to identify patient factors and provider practice patterns...
8.
Kowalchuk R, Van Abel K, Sauer A, Yin L, Garcia J, Harmsen W, et al.
Adv Radiat Oncol
. 2022 Jul;
7(4):100926.
PMID: 35814859
Purpose: Human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV[+]OPSCC) requires further study to optimize the existing clinical staging system and guide treatment selection. We hypothesize that incorporation of the number of...
9.
Price K, Van Abel K, Moore E, Patel S, Hinni M, Chintakuntlawar A, et al.
Int J Radiat Oncol Biol Phys
. 2022 Jun;
114(2):256-265.
PMID: 35675850
Purpose: Patients with human papillomavirus oropharyngeal cancer are highly curable but risk significant long-term toxic effects with standard therapy. This study investigated a de-escalation strategy of decreased adjuvant radiation therapy...
10.
Hassan Nelson L, Fuentes-Bayne H, Yin J, Asmus E, Ryder M, Morris J, et al.
J Endocr Soc
. 2022 Apr;
6(5):bvac044.
PMID: 35402763
Context: Metastatic pheochromocytomas and paragangliomas (mPPGL) are rare vascular neuroendocrine tumors that highly express vascular growth factors. Systemic treatment options in cases of unresectable multisite disease are limited. Multikinase inhibitors...